Trials / Recruiting
RecruitingNCT07346495
A Study of Remternetug (LY3372993) in Healthy Chinese Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Remternetug in Healthy Chinese Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3372993 | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2026-01-31
- Primary completion
- 2026-08-01
- Completion
- 2027-01-01
- First posted
- 2026-01-16
- Last updated
- 2026-03-03
Locations
2 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07346495. Inclusion in this directory is not an endorsement.